University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Pancreas Cancer Program

> UCSF Pancreas Center
> UCSF clinical care for pancreas cancer

Program Leader

temperoMargaret Tempero, MD
Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program;
Professor of Medicine, Division of Hematology and Oncology, UCSF

Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science

Upcoming Event

event flyerUC Pancreatic Cancer Consortium
October 29, 2020 | 8:30 am - 12:00 pm

On Thursday, October 29th, the UC Pancreatic Cancer Consortium will host a half-day virtual symposium on imaging.

View the agenda and register.

Add to Calendar

Funding Opportunities

AACR-AstraZeneca Stimulating Therapeutic Advances through Research Training (START) Grants [more info]
Deadline: October 6, 2020

  • Research Grants: $225,000 over 3 years. Must have completed most recent doctoral degree (or medical residency) within 1–3 years. Projects must address DNA Damage Response pathways or epigenetics.

Shorenstein Foundation Pancreatic Cancer [more info]
Deadline: November 1, 2020

  • Research Grants: $75,000/1 year. A second year may be considered contingent upon receipt of a satisfactory progress report. Only collaborative projects between investigators newly interested in pancreatic cancer and more established pancreas cancer researchers will be considered.

PanCAN Career Development Award [more info]
Deadline: November 20, 2020

  • Research Grants: $200,000 over 2 years. Assistant Professor within 11 years from doctoral degree, and have not received a major grant (R01 or equivalent). Special consideration given to understudied areas in pancreatic cancer research.  

National Pancreas Foundation [more info]
Deadline: January 31, 2021

  • Research Grants: $50,000/1 year. Applicants must be within 10 years of receipt of terminal degree. 

Make a Gift

Make a Gift Pancreatic cancer is the third most common cause of cancer death in the United States. The American Cancer Society estimates that in 2020 about 57,600 people will be newly diagnosed with pancreatic cancer and more than 47,000 people will die from the disease. Pancreatic cancer is a silent killer, as its symptoms are so insidious that most people are not diagnosed until the disease has advanced beyond the stage where surgical resection is possible. Even among surgical candidates, removal of the diseased pancreas and surrounding tissues is rarely curative. To add to this bleak picture, pancreas cancer is also noted for its intrinsic resistance to standard regimens of chemo- and radiotherapy. It is clear that new strategies to prevent, diagnose, and treat pancreas cancer are urgently required.